XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer

CHENGXU CUI1,3*, CHANG SHU2, YI YANG2, JUNBAO LIU3, SHUPING SHI3, ZHUJUN SHAO1, NAN WANG1, TING YANG3 and SONGNIAN HU2

1Department of Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021; 2CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101; 3Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China

Received March 6, 2014; Accepted June 27, 2014

DOI: 10.3892/ol.2014.2335

Abstract. The aim of this study was to compare the efficacy, safety and survival rate of a treatment regimen comprising capecitabine plus irinotecan (XELIRI) to those of a standard regimen comprising leucovorin, fluorouracil and irinotecan (FOLFIRI), to determine the correlation among the inherited genetic variations in UGT1A1, UGT1A7 and UGT1A9. A total of 84 consecutive patients with histologically confirmed metastatic colorectal cancer (mCRC) were included in the study. All patients were treated with FOLFIRI or XELIRI. The median progression-free survival time was 4.4 months for FOLFIRI and 5.7 months for XELIRI (hazard ratio=1.35; 95% confidence interval, 0.83-2.21; P=0.22). When compared with FOLFIRI (63.4%), XELIRI was associated with lower rates of severe toxicity (3.29%) (P=0.026) and similar disease control rates (69.57% for FOLFIRI and 61.11% for XELIRI; P=0.49). In total, 17 single nucleotide polymorphisms were identified, five of which revealed an association with grade 3/4 neutropenia, including UGT1A7*4; however, UGT1A1*28 and UGT1A1*6, which have been previously reported, were not significant. Additionally, H2 haplotypes, which include UGT1A9*22, and H5 and H7 haplotypes, which include UGT1A7*2, UGT1A7*3 and UGT1A7*4, were associated with a higher risk of severe neutropenia. In conclusion, XELIRI is an effective treatment regimen with acceptable response rates and tolerability for mCRC patients as a second-line treatment. Furthermore, inherited genetic variations in UGT1A1, UGT1A7 and UGT1A9 are associated with grade 3/4 neutropenia.

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide (1). In China, CRC accounted for 10.56 and 7.80% of the total cancer incidence and mortality, ranking third and fifth, respectively. The incidence and mortality rate of CRC has continued to increase steadily (2).

Fluorouracil (5-FU) has been the mainstay of treatment for CRC for almost half a century (3). As an oral fluoropyrimidine, capecitabine has been rationally designed to simulate infusional 5-FU (4). Various phase III trials have demonstrated that capecitabine is at least equivalent to 5-FU with respect to progression-free survival (PFS) and overall survival in the first-line treatment of metastatic CRC (mCRC), and exhibits a superior safety profile (5-7).

FOLFIRI, the combination of irinotecan plus fluoropyrimidines, leucovorin (LV) and 5-FU, is a standard second-line treatment option for advanced CRC (8-10). XELIRI is a combination of irinotecan plus capecitabine; therefore, XELIRI includes capecitabine in place of the 5-FU and LV used in the FOLFIRI regimen. As a result, XELIRI may simplify the treatment process and reduce the complications of the central venous catheter that is required for treatment with 5-FU in the FOLFIRI regimen (11-13). However, XELIRI is less commonly used, and is not recognized as a standard chemotherapy regimen. Furthermore, the clinical results available for the XELIRI regimen are limited.

Randomized controlled trials comparing XELIRI with FOLFIRI in the treatment of mCRC have revealed various results. In the BICC-C study, a significantly shorter PFS was noted for the XELIRI regimen, which was also associated with higher toxicity (10). By contrast, in a randomized prospective phase II trial, no significant differences were observed between PFS and toxicity for the XELIRI and FOLFIRI regimens (14). However, the genetic background of patients has been neglected...
in the majority of clinical trials and, therefore, it is possible that these conflicting results are associated with genetic variations. Any administered drug may have a therapeutic effect in certain patients but be ineffective in others. Furthermore, certain patients may suffer adverse effects, where others are unaffected. Personalized medicine is tailored to provide an individualized treatment and to predict the clinical outcome of a variety of treatment regimens. The use of genetic information is one of the core elements in personalized medicine.

The interindividual variability, efficacy and toxicity of irinotecan, which is the common drug in the FOLFIRI and XELIRI regimens, has been attributed predominantly to inherited genetic variations in the UGT1A gene. UGT1A1, UGT1A7 and UGT1A9 are three significant members of the UGT1A subfamily; each isoform comprises a typical exon 1 and four identical downstream exons, and exon 1 is regulated by its own promoter (15). In 2005, the US Food and Drug Administration amended the direction of irinotecan, by appending additional toxicity and dosing warnings relating to the UGT1A1*28 allele (16). Whilst the frequency of UGT1A1*28 is low in East Asian populations, UGT1A1*6, which has only been identified in Asian populations, has been associated with toxicity in patients treated with irinotecan (17,18). UGT1A7 and UGT1A9 genotypes have also been reported to be predictors of response and toxicity in patients treated with irinotecan-based regimens (19). However, the toxicity and efficacy of irinotecan remains unpredictable.

The aim of the current study was to compare the efficacy, safety and survival rate of the XELIRI regimen to those of the standard FOLFIRI regimen. The functional regions of UGT1A1, UGT1A7 and UGT1A9 were sequenced and comprehensively analyzed for genetic polymorphisms, to determine the correlation between inherited genetic variations, and the efficacy and safety of these irinotecan-based regimens.

### Patients and methods

**Patients.** Between 2009 and 2013 at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Beijing, China), a total of 84 consecutive patients with histologically confirmed mCRC were included in the study. Each patient provided written informed consent. All patients were treated with FOLFIRI or XELIRI. The study was approved by the ethics committee of Beijing Chao-Yang Sanhuan Cancer Hospital (Beijing, China).

**Eligibility criteria.** The following inclusion criteria were used in this study: Age, >18 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2; adequate bone marrow, hepatic and renal function (absolute neutrophil count, >1,500/µl; hemoglobin levels, >9.0 g/dl; platelet count, >75,000/µl; total serum bilirubin levels, <1.5-fold the upper normal limit (UNL); alanine aminotransferase/aspartate aminotransferase ratio, <2.5-fold the UNL; and serum creatinine levels, <1.6 mg/dl or creatinine clearance, >40 ml/min).

**Exclusion criteria.** The exclusion criteria included the following: Inadequately controlled hypertension; unstable angina pectoris; and history of myocardial infarction, stroke or transient ischemic attack, pulmonary embolism, or deep vein thrombosis within six months prior to treatment.

### Table I. Primer sequences.

| Genes     | Primer ID | Primer sequences               |
|-----------|-----------|--------------------------------|
| UGT1A1    | U1_E1AF   | TCGTCCCTTTCTCTCTCTCTGG         |
|           | U1_E1AR   | GCAAGTCATGCAAGAACATGGAAT       |
|           | U1_E1BF   | TGTCTGGCTTTCCTCCACTTA          |
|           | U1_E1BR   | CCAAGAAGATGATGCCAAAGA          |
|           | U1_PF     | GTTCATTCTCTACCCCCACGCA         |
|           | U1_PR     | AAAAGCTGTACGGTCCACAAAAAGG      |
| UGT1A7    | U7_E1AF   | AACTCATATGAGCAGCACAG           |
|           | U7_E1AR   | AGCTCAAAAATACCATTGGATGAA       |
|           | U7_E1BF   | GGAAGATCCTGAATTGCCAGG          |
|           | U7_E1BR   | TTCTCTGGGAGTATGTGAGAA          |
|           | U7_PF     | TTCTCTGGGAGTATGTGAGGA          |
|           | U7_PR     | CACATTCACTGGCAAATTTA           |
| UGT1A9    | U9_E1AF   | CCAAGGCAAGAGACCATAAGCTA        |
|           | U9_E1AR   | CAAACTCCTGCAATTGGAAAA          |
|           | U9_E1BF   | CATATACCCTGAGATCTGGGA          |
|           | U9_E1BR   | CAGCAGATGACCGCATGTTG           |
|           | U9_PF     | CCTCTGAGCTCAAGGAGTGGA          |
|           | U9_PR     | CAATGATTACCCAAAAAGAAAG        |

F, forward; R, reverse.
Chemotherapy. The FOLFIRI or XELIRI regimen was administered until progressive disease (PD), unacceptable toxicity, patient refusal or a medical decision to discontinue treatment. The FOLFIRI regimen consisted of 180 mg/m² irinotecan intravenously (IV) over 90 min, 400 mg/m² LV IV over 2 h, and 400 mg/m² 5-FU IV bolus, followed by 2,400 mg/m² 5-FU

Table II. Baseline patient characteristics.

| Characteristics       | FOLFIRI (n=46) | XELIRI (n=38) | P-value |
|-----------------------|---------------|---------------|---------|
| Age, years            |               |               | 0.49    |
| Median                | 54            | 53            |         |
| Range                 | 29-77         | 30-72         |         |
| BSA, m²               |               |               | 0.21    |
| Median                | 1.78          | 1.73          |         |
| Range                 | 1.42-2.10     | 1.40-2.00     |         |
| Gender                |               |               | 0.17    |
| Male                  | 33            | 21            |         |
| Female                | 13            | 17            |         |
| Primary tumor site    |               |               | 0.66    |
| Colon                 | 28            | 25            |         |
| Rectum/rectosigmoid   | 18            | 13            |         |
| Metastatic sites      |               |               | 0.41    |
| 1                     | 18            | 11            |         |
| 2                     | 21            | 17            |         |
| ≥3                    | 7             | 10            |         |
| ECOG PS               |               |               | 0.33    |
| 0                     | 12            | 11            |         |
| 1                     | 34            | 25            |         |
| 2                     | 0             | 2             |         |
| TNM stage             |               |               | 0.27    |
| IIIB                  | 4             | 1             |         |
| IIIC                  | 0             | 1             |         |
| IV                    | 42            | 36            |         |

FOLFIRI, leucovorin, fluorouracil and irinotecan; XELIRI, capecitabine and irinotecan; BSA, body surface area; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor node metastasis.

Table III. Responses to treatment.

| Response | FOLFIRI (n=46) | XELIRI (n=38) | P-value |
|----------|---------------|---------------|---------|
| CR       | 0             | 0             | 0.59    |
| PR       | 10            | 5             |         |
| SD       | 22            | 17            |         |
| PD       | 14            | 14            |         |
| Not assessable | 0 | 2 | |
| Overall response | 10 | 5 | 0.40 |
| Disease control  | 32 | 22 | 0.49 |

aDifference among the whole distribution of CR/PR/SD/PD; bCR + PR; cCR + PR + SD. FOLFIRI, leucovorin, fluorouracil and irinotecan; XELIRI, capecitabine and irinotecan; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
IV over a 46-h infusion, all administered on day one, every two weeks. The XELIRI regimen consisted of 120 mg/m² irinotecan IV on days one and eight, and 800 mg/m² oral capecitabine twice per day on days one to 14, repeated every three weeks. Evaluation and statistical analysis. Baseline evaluations consisted of physical examination, complete medical history, electrocardiography, ECOG PS, a complete blood count, hepatic and renal function tests, and assessment of serum

### Table IV. Drug-related adverse events.

| Response          | FOLFIRI (n=46) | XELIRI (n=38) | P-value |
|-------------------|----------------|---------------|---------|
|                   | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | |
| Hematological events |           |           |           |            |           |           |           |           | |
| Anemia            | 20        | 43.48     | 1         | 2.17       | 19        | 50.00     | 2         | 5.26       | 0.58     |
| Leukopenia        | 22        | 47.83     | 8         | 17.39      | 18        | 47.37     | 4         | 10.53      | 0.66     |
| Neutropenia       | 14        | 30.43     | 12        | 26.09      | 18        | 47.37     | 2         | 5.26       | **0.03** |
| Thrombocytopenia  | 9         | 19.57     | 2         | 4.35       | 9         | 23.68     | 0         | 0.00       | 0.59     |
| Non-hematological events |   |           |           |            |           |           |           |           |         |
| Asthenia          | 1         | 2.17      | 0         | 0.00       | 3         | 7.89      | 0         | 0.00       | 0.32     |
| Nausea            | 39        | 84.78     | 5         | 10.87      | 33        | 86.84     | 2         | 5.26       | 0.58     |
| Vomiting          | 28        | 60.87     | 5         | 10.87      | 27        | 71.05     | 2         | 5.26       | 0.54     |
| Mucositis         | 1         | 2.17      | 0         | 0.00       | 1         | 2.63      | 0         | 0.00       | 1.00     |
| Diarrhea          | 10        | 21.74     | 2         | 4.35       | 13        | 34.21     | 2         | 5.26       | 0.39     |
| Neurotoxicity     | 2         | 4.35      | 0         | 0.00       | 3         | 7.89      | 0         | 0.00       | 0.65     |
| Hand-foot syndrome| 0         | 0.00      | 0         | 0.00       | 1         | 2.63      | 0         | 0.00       | 0.45     |
| Allergies         | 0         | 0.00      | 0         | 0.00       | 1         | 2.63      | 1         | 2.63       | 0.20     |

Bold P-value indicates significance (P<0.05). FOLFIRI, leucovorin, fluorouracil and irinotecan; XELIRI, capecitabine and irinotecan.

### Table V. Association of UGT1A polymorphisms with efficacy.

| Genes | SNP ID | Allele | MAF | Overall response | Disease control |
|-------|--------|--------|-----|------------------|-----------------|

| UGTIA9 | rs3806598 | 0.295 | 0.605 | 0.605 |
|--------|-----------|-------|-------|-------|
|        | rs45440791| 0.023 | 0.613 | 0.613 |
|        | rs59870334| 0.429 | 0.767 | 0.670 |
| UGTIA7 | rs4530361 | 0.295 | 0.605 | 0.605 |
|        | rs28946877| 0.167 | 0.168 | 0.949 |
|        | rs7586110 | 0.310 | 0.685 | 0.290 |
|        | rs7577677 | 0.295 | 0.605 | 0.605 |
|        | rs17868323| 0.432 | 0.749 | 0.749 |
|        | rs66534818| 0.432 | 0.749 | 0.749 |
|        | rs17868324| 0.432 | 0.749 | 0.749 |
|        | rs11692021| 0.295 | 0.605 | 0.605 |
|        | rs45462096| 0.023 | 0.000 | 0.000 |
|        | rs17864686| 0.159 | 0.184 | 0.825 |
| UGTIA1 | rs887829  | 0.091 | 0.368 | 0.548 |
|        | rs873478  | 0.045 | 0.468 | 0.468 |
|        | rs34815109| 0.114 | 0.292 | 0.792 |
|        | rs4148323 | 0.250 | 0.361 | 0.068 |

| P-value\textsuperscript{b} | |

\textsuperscript{a}SNP ID not available for all alleles; \textsuperscript{b}Pearson's \(\chi^2\) test. SNP, single nucleotide polymorphism; MAF, minor allele frequency.
Table VI. Correlation between UGT1A polymorphisms and severe toxicity.

| Genes   | SNP ID     | Allelea | MAF  | Anemia | Neutropenia | Leukopenia | Thrombocytopenia | Nausea | Vomiting | Diarrhea | Allergies | Severe toxicity |
|---------|------------|---------|------|--------|-------------|------------|------------------|--------|----------|----------|-----------|-----------------|
| UGT1A9  | rs3806598  | 0.295   | 0.349 | 0.032  | 0.237       | 0.516      | 0.516            | 0.516  | 0.347    | 0.516    | 0.516     | 0.119           |
|         | rs45440791 | 0.023   | 0.825 | 0.688  | 0.825       | 0.825      | 0.749            | 0.825  | 0.445    |          |           |                 |
|         | rs59870334 | 0.429   | 0.834 | 0.203  | 0.834       | 0.000      | 0.000            | 0.762  | 0.834    | 0.186    |           |                 |
|         | UGT1A9*22  |         |       |        |             |            |                  |        |          |          |           |                 |
| UGT1A7  | rs4530361  | 0.295   | 0.349 | 0.032  | 0.237       | 0.516      | 0.516            | 0.516  | 0.347    | 0.516    | 0.516     | 0.119           |
|         | rs28946877 | 0.167   | 0.195 | 0.237  | 1.000       | 0.517      | 0.000            | 0.000  | 0.347    | 0.517    | 0.770     |                 |
|         | rs7586110  | 0.310   | 0.332 | 0.041  | 0.276       | 0.551      | 0.000            | 0.000  | 0.386    | 0.551    | 0.238     |                 |
|         | rs7577677  | 0.295   | 0.349 | 0.032  | 0.237       | 0.516      | 0.349            | 0.349  | 0.347    | 0.516    | 0.382     |                 |
|         | rs17868323 | 0.432   | 0.842 | 0.211  | 0.842       | 0.207      | 0.207            | 0.773  | 0.842    | 0.490    |           |                 |
|         | UGT1A7*2 and *3 | 0.432 | 0.842 | 0.211  | 0.842       | 0.207      | 0.207            | 0.773  | 0.842    | 0.490    |           |                 |
|         | rs66534818 | 0.432   | 0.842 | 0.211  | 0.842       | 0.207      | 0.207            | 0.773  | 0.842    | 0.490    |           |                 |
|         | UGT1A7*2 and *3 | 0.432 | 0.842 | 0.211  | 0.842       | 0.207      | 0.207            | 0.773  | 0.842    | 0.490    |           |                 |
|         | rs17868324 | 0.432   | 0.842 | 0.211  | 0.842       | 0.207      | 0.207            | 0.773  | 0.842    | 0.490    |           |                 |
|         | UGT1A7*2 and *3 | 0.432 | 0.842 | 0.211  | 0.842       | 0.207      | 0.207            | 0.773  | 0.842    | 0.490    |           |                 |
|         | rs11692021 | 0.295   | 0.349 | 0.032  | 0.237       | 0.516      | 0.516            | 0.516  | 0.347    | 0.516    | 0.516     | 0.119           |
|         | UGT1A7*3 and *4 | 0.295 | 0.349 | 0.032  | 0.237       | 0.516      | 0.516            | 0.516  | 0.347    | 0.516    | 0.516     | 0.119           |
|         | rs45462096 | 0.023   | 0.825 | 0.688  | 0.011       | 0.825      | 0.825            | 0.825  | 0.749    | 0.825    | 0.825     | 0.181           |
|         | rs17864686 | 0.159   | 0.177 | 0.252  | 0.957       | 0.529      | 0.529            | 0.529  | 0.362    | 0.529    | 0.640     |                 |
|         | UGT1A1     | rs887829 | 0.091 | 0.647  | 0.405       | 0.487      | 0.647            | 0.647  | 0.507    | 0.647    | 0.620     |                 |
|         | rs873478   | 0.045   | 0.002 | 0.565  | 0.565       | 0.752      | 0.752            | 0.752  | 0.647    | 0.752    | 0.682     |                 |
|         | rs34815109 | 0.114   | 0.604 | 0.660  | 0.660       | 0.604      | 0.604            | 0.604  | 0.604    | 0.453    | 0.604     | 0.858           |
|         | UGT1A1*28  |         |       |        |             |            |                  |        |          |          |           |                 |
|         | rs4148323  | 0.250   | 0.403 | 0.128  | 0.612       | 0.403      | 0.403            | 0.403  | 1.000    | 0.403    | 0.469     |                 |

aSNP ID not available for all alleles; bPearson’s $\chi^2$ test. Bold P-value indicates significance (P<0.05). SNP, single nucleotide polymorphism; MAF, minor allele frequency.
carcinoembryonic antigen levels. All patients received an abdominopelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan, and chest X-ray or CT/MRI of the chest. During treatment, a follow-up CT/MRI of the abdomen and pelvis, and chest X-ray or chest CT/MRI were performed every six weeks. Assessments were performed every three courses until PD or upon the discontinuation of chemotherapy. Tumor response classification was based on the Response Evaluation Criteria in Solid Tumors guidelines (20), while toxicity was graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0 (21).

The primary efficacy endpoint was PFS, which was defined as the time from initiation of treatment to the first documentation of PD, or to the date of mortality or loss to follow-up. The secondary efficacy endpoint included overall response (complete + partial response) and toxicity.

For the comparison of the two chemotherapy regimens, Fisher's exact test and Student's t-test were used. Kaplan-Meier method was used for PFS analysis. The hazard ratio (HR) and 95% confidence interval (CI) for the treatment comparisons were obtained from a Cox proportional hazards model. All statistical tests were two-sided, and P<0.05 was considered to indicate a statistically significant difference between the two treatment regimens. All results were analyzed using IBM SPSS 19.0 software (IBM, Armonk, NY, USA).

Genotyping and genetic analysis. Blood samples were obtained from 22 mCRC patients (10 placed into the FOLFIRI group and 12 into the XELIRI group) for isolation of genomic DNA at least one week prior to commencing chemotherapy. Genomic DNA was isolated from peripheral blood samples using the QIAamp DNA blood mini kit (Qiagen, Valencia, CA, USA). To screen the single nucleotide polymorphisms (SNPs) in UGT1A1, UGT1A7 and UGT1A9, the gene regions were sequenced, including its promoter and exon 1, using the DYEnamic ET terminator cycle sequencing kit (GE Healthcare, Chalfont St. Giles, UK) on the ABI Prism 3730xl DNA analyzer (Applied Biosystems, Foster City, CA, USA). Following pre-denaturation at 93°C for 3 min, amplification was performed under the following conditions for 32 cycles: Denaturation at 95°C for 30 sec; annealing at 58°C for 40 sec; and extension at 72°C for 2 min. The primer sequences used are shown in Table I.

All sequences were analyzed with Phred, Phrap, Consed and Polyphred programs (University of California, Oakland, CA, USA; http://elcapitan.ucsd.edu/hyper/polyphred.usage.html) and were compared with the reference sequence NC_000002.11 to evaluate genetic variations. Estimating allele frequencies, testing the Hardy-Weinberg equilibrium, measuring pairwise linkage disequilibrium (LD) and estimating haplotype frequency were performed using Haplovew 4.2 (Broad Institute of MIT and Harvard, Cambridge, MA, USA; http://www.broad.mit.edu/mpg/haplovew/). Correlations between the SNPs or haplotypes and toxicity or response were analyzed by Pearson’s $\chi^2$ test. On account of the exploratory nature of this study, no adjustments were made for multiple comparisons.

| Block | ID | Haplotype | MAF  | Overall response | Disease control |
|-------|----|-----------|------|------------------|-----------------|
| 1     | H1 | ATA       | 0.564| 0.725            | 0.544           |
|       | H2 | CAG       | 0.295| 0.605            | 0.605           |
|       | H3 | AAA       | 0.141| 0.222            | 0.851           |
| 2     | H4 | TCTCGT    | 0.545| 0.633            | 0.753           |
|       | H5 | GAGAAC    | 0.272| 0.478            | 0.862           |
|       | H6 | TCGAAT    | 0.136| 0.232            | 0.232           |
|       | H7 | GAGAAT    | 0.023| 0.614            | 0.045           |
|       | H8 | TCTCGC    | 0.015| 0.692            | 0.118           |

*Pearson’s $\chi^2$ test. Bold P-value indicates significance (P<0.05). MAF, minor allele frequency.
Results

Patient characteristics. Between 2009 and 2013 at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, a total of 84 consecutive patients with histologically confirmed mCRC were included in this study. In total, 46 patients were treated with the FOLFIRI regimen and 38 patients received the XELIRI regimen. The patient baseline characteristics of the two chemotherapy regimens are summarized in Table II. No statistically significant differences were observed between the baseline characteristics for the two regimens.

Efficacy. The efficacy of the treatment groups is shown in Table III. The disease control rates did not differ significantly between the two chemotherapy arms (69.57% for FOLFIRI and 61.11% for XELIRI; P=0.49). Although the overall response rate of the FOLFIRI group was markedly higher than that of the XELIRI group (21.74% for FOLFIRI and 13.89% for XELIRI), the differences in the overall response rate between the two groups did not appear to be statistically significant (P=0.40). The PFS of patients in the FOLFIRI and XELIRI groups is presented in Fig. 1. The median PFS time for the patients in the FOLFIRI group was 4.4 months, and 5.7 months in the XELIRI group. Although PFS improved for patients who received XELIRI when compared with FOLFIRI, no statistically significant differences were observed in PFS between the two groups (HR=1.35 for disease progression or mortality; 95% CI, 0.83-2.21; P=0.22).

Tolerability. Adverse events of any grade in the FOLFIRI and XELIRI treatment groups are shown in Table IV. The most common grade 3/4 adverse events associated with FOLFIRI and XELIRI were neutropenia (26.09% in the FOLFIRI group and 5.26% in the XELIRI group) and leukopenia (17.39% in the FOLFIRI groups and 10.53% in the XELIRI group). FOLFIRI was associated with higher rates of grade 3/4 leukopenia, neutropenia, thrombocytopenia, nausea and vomiting. However, these differences were not statistically significant, with the exception of neutropenia, which was the most frequently reported grade 3/4 hematological toxicity (P=0.03). Hand-foot syndrome is the most common adverse event associated with capecitabine; however, no hand-foot syndrome of grade 3/4 occurred in either of these two groups.

Inherited genetic variations in UGT1A gene. In total, 17 SNPs were identified across the sequencing regions of the UGT1A1, UGT1A7 and UGT1A9 genes; all of the SNPs under investigation were in Hardy-Weinberg equilibrium (P>0.05). However, no significant correlation was observed for efficacy (Table V). Certain SNPs exhibited an association with severe toxicity; however, UGT1A1*28 and UGT1A1*6, which have been previously reported (17,18), were not significant (Table VI).

Among the detected variants, only the common SNPs with a minor allele frequency (MAF) of >10% were tested for pairwise LD. Two main linkage blocks were observed across the sequenced region, while two major haplotypes were identified by haplotype analysis using Haplovew; ATA in block one (56.4%) and TCTCGT in block two (54.5%). Haplotype H7,
which includes UGT1A7*2, UGT1A7*3 and UGT1A7*4, was found to correlate with the disease control rate (P=0.045) (Table VII); while haplotypes H2 and H5 were observed to correlate with a higher risk of severe neutropenia (Table VIII).

Discussion

A number of phase II studies on XELIRI have suggested acceptable response rates and tolerability (22,23). However, in the phase III study by Fuchs et al (10), a significantly shorter PFS was noted for the XELIRI regimen, which was also associated with higher rates of severe vomiting, diarrhea and dehydration.

The present study investigated the second-line treatment of mCRC, and demonstrated that the XELIRI regimen, which is composed of irinotecan with oral capecitabine, offers similar disease control rates (69.57% for FOLFIRI and 61.11% for XELIRI; P=0.49) and longer PFS (median, 4.4 months for FOLFIRI and 5.7 months for XELIRI) when compared with FOLFIRI. Additionally, grade 3/4 leukopenia, neutropenia, thrombocytopenia, nausea and vomiting were less frequently observed in patients treated with the XELIRI regimen when compared with the FOLFIRI regimen; however, these were not significant, with the exception of neutropenia (P=0.03). Furthermore, no occurrence of hand-foot syndrome of grade 3/4 was observed in the XELIRI treatment group, which is the most common adverse event associated with capecitabine.

Taking the physical health of the patients into account, the dose of oral capecitabine was reduced to 800 mg/m² twice a day on days 1-14. The lower overall response rate (21.74% for FOLFIRI and 13.89% for XELIRI; P=0.40) and reduced toxicity may result from the lower doses of the combination of capecitabine and irinotecan. Alternatively, another reason for this may be that the patients neglect one or more doses of the regular dosing schedule, as capecitabine is an oral drug that must be self-taken by the patient at home.

In conclusion, the present study demonstrated that XELIRI is an effective treatment regimen with acceptable response rates and tolerability for mCRC patients as a second-line treatment in addition to FOLFIRI.

Irinotecan, which is the common drug in FOLFIRI and XELIRI regimens, has a narrow therapeutic range, and severe toxicity may limit the dose that can be safely administered (24). The increasing knowledge of human genetic variations is likely to aid with personalized treatment.

The current study is different from previous studies, which have concentrated more on several specific alleles, including UGT1A1*28, UGT1A1*6, UGT1A7*2 and UGT1A9*22 (17,18,25,26). In order to obtain further information, the promoter and exon 1 of UGT1A1, UGT1A7 and UGT1A9 were screened, and 17 SNPs as well as two main linkage blocks were identified. When only the SNPs and haplotypes with MAF of >10% were considered to minimize the statistical discrepancy, no significant correlation with treatment efficacy was observed. In total, five SNPs were identified to reveal a correlation with grade 3/4 neutropenia, including UGT1A7*4; however, the correlation with UGT1A1*28 and UGT1A1*6, which has been repeatedly reported, was not significant. Furthermore, the H2 haplotype, which includes UGT1A9*22, and the H5 and H7 haplotypes, which include UGT1A7*2, UGT1A7*3 and UGT1A7*4, were associated with an increased risk of severe neutropenia. The limitations of this study are the exploratory nature and the limited sample size. Therefore, the results must be confirmed by additional studies comprising a larger number of patients and a more comprehensive assessment of variations in UGT1A in the future.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Chen Q, Liu ZC, Cheng LP, et al: An analysis of incidence and mortality of colorectal cancer in China, 2003-2007. China Cancer 21: 179-182, 2012 (In Chinese).
3. Meropol NJ: Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 34: 1509-1513, 1998.
4. Mayer RJ: Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol 19: 4093-4096, 2001.
5. Masarutti B, Gómez A, Sastre J, et al: Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC). J Clin Oncol 24 (Suppl 18): S165, 2006.
6. Díaz-Rubio E, Tabernero J, Gómez-España A, et al; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial: Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25: 4224-4230, 2007.
7. Tol J, Koopman M, Rodenburg CJ, et al: A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19: 734-738, 2008.
8. Cunningham D, Pyrhönen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
9. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
10. Fuchs CS, Moore MR, Harker G, et al: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814, 2003.
11. Munoz A, Salud A, Giron CG, et al: Randomised phase III trial comparing irinotecan plus bevacizumab (XELIRI regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC). Ann Oncol 17 (Suppl 9): S120, 2006.
12. Koopman M, Antonini NF,Douma J, et al: 3015 ORAL Sequential vs. combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study, Eur J Cancer (Suppl 5): S239-S240, 2007.
13. Pectasides D, Papaxonis G, Kalogeras KT, et al: XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer 12: 271, 2012.
14. Skol E, Rebersek M, Hlebanz J and Ocvirk J: Capecitabine plus Irinotecan (XELIRI) regimen compared to 5-FU/LV plus Irinotecan (FOLFIRI) regimen as neoadjuvant treatment for patients with unresectable liver-only metasteses of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9: 120, 2009.
15. Lévesque E, Bélanger AS, Harvey Met al: Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-Fluorouracil/irinotecan-based regimens. J Pharmocol Exp Ther 345: 95-101, 2013.
16. Ratain MJ: From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res 12: 1658-1660, 2006.
17. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237-2244, 2006.
18. Takano M, Kato M, Yoshikawa T, et al: Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76: 315-321, 2009.
19. Carlini LE, Meropol NJ, Bever J, et al: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: 1226-1236, 2005.
20. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
21. Ajani JA, Welch SR, Raber MN, Fields WS and Krakoff IH: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147-159, 1990.
22. Borner MM, Bernhard J, Dietrich D, et al; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16: 282-288, 2005.
23. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al: A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16: 1123-1132, 2005.
24. Mathijssen RH and Gurney H: Irinogenetics: how many stars are there in the sky? J Clin Oncol 27: 2578-2579, 2009.
25. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382-1388, 2004.
26. Cucchin E, Innocenti F, D'Andrea M, et al: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27: 2457-2465, 2009.